Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial.

Objective: To evaluate the efficacy and safety of intraarticular sprifermin (recombinant human fibroblast growth factor 18) in the treatment of symptomatic knee osteoarthritis (OA).

Methods: The study was a randomized, double-blind, placebo-controlled, proof-of-concept trial. Intraarticular sprifermin was evaluated at doses of 10 μg, 30 μg, and 100 μg.

Longitudinal (one-year) change in cartilage thickness in knees with early knee osteoarthritis: A within-person between-knee comparison.

Objective: To test the hypothesis that cartilage displays significant longitudinal thickening in the external subregions of the central medial (ecMF) and lateral (ecLF) femur in knees with early radiographic osteoarthritis (ROA) compared with contralateral knees without ROA, and to explore differences in change in other subregions and in radiographic joint space width (JSW). Methods: 50 participants (50% women; age 61.1±9.

Femorotibial Cartilage Thickness Change Distributions for Subjects without Signs, Symptoms, or Risk Factors of Knee Osteoarthritis.

Objective: To describe the distribution of longitudinal femorotibial cartilage thickness annualized rate of change (ΔThCtAB) from quasi-population-based studies, and to construct a reference distribution for men and women without signs, symptoms, or risk factors of knee osteoarthritis (OA).

Methods: Segmented baseline and 1-year follow-up MRI from 43 men and 69 women of the Osteoarthritis Initiative (OAI) asymptomatic control cohort without risk factors and also baseline and 2-year follow-up data from 77 asymptomatic women of the Pfizer A9001140 study were included. The mean, standard deviation (SD), and correlation of ΔThCtAB in medial and lateral femorotibial subregions were estimated; distributions were tested for normality and for differences between cohorts and gender.